SIRPα(+) macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab

Limited data exist regarding the outcome of patients with follicular lymphoma (FL) who relapse or progress after frontline lenalidomide and rituximab (R(2)). Moreover, mechanisms of resistance to R(2) in FL remain unclear, with increased protumoral macrophages suspected as a major contributory culpr...

Descripción completa

Detalles Bibliográficos
Autores principales: Marques-Piubelli, Mario L., Parra, Edwin R., Feng, Lei, Soto, Luisa Solis, Gallardo, Mariana, Gouni, Sushanth, Samaniego, Felipe, Noorani, Mansoor, Hagemeister, Fredrick B., Westin, Jason R., Lee, Hun Ju, Rodriguez, Maria A., Neelapu, Sattva S., Gunther, Jillian R., Fowler, Nathan H., Flowers, Christopher R., Wistuba, Ignacio I., Nastoupil, Loretta J., Vega, Francisco, Strati, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198921/
https://www.ncbi.nlm.nih.gov/pubmed/35359004
http://dx.doi.org/10.1182/bloodadvances.2022007104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198921/
https://www.ncbi.nlm.nih.gov/pubmed/35359004
http://dx.doi.org/10.1182/bloodadvances.2022007104

Ejemplares similares